title: [Effects of opiate receptor blockade with naloxone on prolactin (PRL) secretion in patients with diabetes type I (IDDM) with chronic renal failure treated with hemodialysis (HD)].
abstract: The aim of the study was to answer the questions: 1) does the prolactin secretion in the TRH test (0.4 mg i.v.) differ in haemodialyzed patients with diabetes nephropathy in the end stage renal failure in comparison to haemodialyzed chronic renal failure patients with non-diabetic nephropathy and healthy subjects; 2) does the opiate receptors blockade with naloxone (2 mg i.v.) modify the prolactin secretion during the TRH test in those patients. 39 subjects were studied. The patients were divided into three groups: group I: 12 haemodialyzed patients with IDDM and diabetic nephropathy in the end stage renal failure, group II: 15 haemodialyzed chronic renal patients with non-diabetic nephropathy and the control group: 12 healthy persons. The basic prolactin secretion and area over basic value (AOBV) of the prolactin were estimated. Prolactin concentration was measured by LIA. 1) The basic prolactin secretion was significantly higher in the patients with chronic renal failure. 2) The basic prolactin secretion in IDDM patients with diabetic nephropathy in the end stage renal failure treated with haemodialysis was significantly lower than in haemodialyzed patients with chronic renal failure of non-diabetic etiology. 3) TRH and TRH with naloxone caused significant increase of prolactin secretion in all investigated groups, but the increase is significantly lower in chronic renal failure patients than in healthy subjects. 4) Naloxone decreases significantly the prolactin secretion during TRH test only in haemodialyzed patients with chronic renal failure of non-diabetic etiology.
authors.affiliation: Katedra i Klinika Chorób Wewnetrznych i Zawodowych Slaskiej AM w Zabrzu.
authors.forename: D
authors.initials: D
authors.lastname: Moczulski
authors.forename: E
authors.initials: E
authors.lastname: Zukowska-Szczechowska
authors.forename: W
authors.initials: W
authors.lastname: Grzeszczak
authors.forename: J
authors.initials: J
authors.lastname: Gumprecht
authors.forename: M
authors.initials: M
authors.lastname: Liszka
authors.forename: M
authors.initials: M
authors.lastname: Snit
authors.forename: J
authors.initials: J
authors.lastname: Gawron
mesh_terms: D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000097:blood*; D003928:Diabetic Nephropathies / Q000097:blood* / Q000628:therapy; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D008875:Middle Aged; D009270:Naloxone / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000494:pharmacology*; D011388:Prolactin / Q000097:blood / Q000187:drug effects*; D006435:Renal Dialysis
chemical_list: D009292:Narcotic Antagonists; D009270:Naloxone; D011388:Prolactin